Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions T-cell Lymphoma, NK-Cell Lymphoma, T-cel...
Phase Not Applicable
Enrollment 1000
Locations 26 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Optional Blood Sample and Nail Sample — Participants may provide optional research blood and nail samples for biobanking and future use

Primary Outcomes

  • Number of participants populating the T-cell Lymphoma Master Repository/TCLMR (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-27
Completion: 2030-07-27
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Steven Horwitz, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Steven Horwitz, MD
646-608-2680
horwitzs@MSKCC.ORG
Alison Moskowitz, MD
646-608-3726
moskowia@mskcc.org
Jasmine Zain, MD
626-359-8111
City of Hope Cancer Center (Data collection only)
Interventions
  • Other: Optional Blood Sample and Nail Sample — Participants may provide optional research blood and nail samples for biobanking and future use
Study Locations (26 sites)
City of Hope Cancer Center (Data collection only), Duarte, California 91010 United States
UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego, California 92103 United States
University of California San Francisco (Data collection only), San Francisco, California 94143 United States
Stanford University Medical Center (Data collection only), Stanford, California 94305-5408 United States
University of Colorado (Data Collection Only), Aurora, Colorado 80045 United States
Yale University (Data Collection Only), New Haven, Connecticut 06511 United States
University of Miami (Data Collection Only), Miami, Florida 33136 United States
Moffitt Cancer Center (Data Collection Only), Tampa, Florida 33612 United States
Emory University (Data Collection Only), Atlanta, Georgia 30322 United States
Northwestern Medicine (Data Collection), Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy. * Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines): * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Aggressive NK-cell leukemia * Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood * Chronic active EBV infection of T- and NK-cell type, systemic form * Hydroa vacciniforme-like lymphoproliferative disorder * Adult T-cell leukemia/lymphoma * Extranodal NK/T-cell lymphoma, nasal type * Enteropathy-associated T-cell lymphoma * Monomorphic epitheliotropic intestinal T-cell lymphoma * Intestinal T-cell lymphoma, not otherwise specified (NOS) * Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract * Hepatosplenic T-cell lymphoma * Subcutaneous panniculitis-like T-cell lymphoma * Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy) * Sézary syndrome * Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy) * Primary cutaneous Gamma-Delta T-cell lymphoma * Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma * Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy) * Peripheral T-cell lymphoma, not otherwise specified * Angioimmunoblastic T-cell lymphoma * Follicular T-cell lymphoma * Nodal peripheral T-cell lymphoma with TFH phenotype * Anaplastic large cell lymphoma, ALK-positive * Anaplastic large cell lymphoma, ALK-negative * Breast-implant associated anaplastic large cell lymphoma. * NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy. Exclusion Criteria: * Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy. * Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.
Conditions Lymphoma
Phase Not Applicable
Enrollment 16000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Database of Institut Paoli-Calmettes patients diagnosed with lymphoma

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Data collection

Primary Outcomes

  • Survival of patients (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2000-01
Completion: 2030-12
Eligibility
Age: 18 Years – 95 Years
Sex: ALL
Volunteers: false
Enrollment: 16000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Paoli-Calmettes
Contact Information
Study Contact:
Dominique Genre, MD
0033491223778
drci.up@ipc.unicancer.fr
Lilian Laborde
0033491223778
labordel@ipc.unicancer.fr
Dominique GENRE, MD
+33 4 91 22 37 78
drci.up@ipc.unicancer.fr
Institut Paoli-Calmettes
Interventions
  • Other: Data collection
Study Locations (1 sites)
Institut Paoli-Calmettes, Marseille, Bouches-du Rhône 13009 France
Eligibility Criteria
Inclusion Criteria: * Hodgkin or non-hodgkin lymphoma Exclusion Criteria: * Non applicable
Conditions Metastatic Cancer, Breast Cancer, Lobula...
Phase PHASE2
Enrollment 8
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: 18F-fluorofuranylnorprogesterone — The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.
  • Device: Liquid Biopsy — 20ml of whole blood will be collected into two Ethylenediaminetetraacetic acid (EDTA) tubes at each timepoint, CTCs are isolated using the microfluidic Versatile Exclusion-based Rare Sample Analysis (VERSA) platform that integrates CTC capture with RNA extraction on a single chip using Exclusion-Based Sample Preparation (ESP) technology
  • Device: Positron Emission Tomography/Computed Tomography — FFNP drug in combination with PET/CT scans to image participant

Primary Outcomes

  • Number of Participants who have decreased FFNP uptake on PET/CT in response to endocrine therapy (baseline, 4 weeks)
  • Number of Participants who have decrease in circulating tumor cell estrogen signaling in response to endocrine therapy (baseline, 4 weeks)
  • Number of Participants who have a decrease in concentration of Circulating Tumor DNA in response to endocrine therapy (baseline, 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-30
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 8 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Wisconsin, Madison
Principal Investigators:
  • Marina Sharifi, MD, PHD (PRINCIPAL_INVESTIGATOR) - UW Carbone Cancer Center
Contact Information
Study Contact:
Cancer Connect
800-622-8922
clinicaltrials@cancer.wisc.edu
Interventions
  • Drug: 18F-fluorofuranylnorprogesterone — The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.
  • Device: Liquid Biopsy — 20ml of whole blood will be collected into two Ethylenediaminetetraacetic acid (EDTA) tubes at each timepoint, CTCs are isolated using the microfluidic Versatile Exclusion-based Rare Sample Analysis (VERSA) platform that integrates CTC capture with RNA extraction on a single chip using Exclusion-Based Sample Preparation (ESP) technology
  • Device: Positron Emission Tomography/Computed Tomography — FFNP drug in combination with PET/CT scans to image participant
Study Locations (1 sites)
UW Carbone Cancer Center, Madison, Wisconsin 53792 United States
Eligibility Criteria
Inclusion Criteria: 1. Willing to provide informed consent 2. Individuals at least 18 years of age 3. Have biopsy-proven ER/PR-positive (defined as ER ≥1 percent and PR ≥1 percent by IHC) and HER2-negative advanced or metastatic LBC starting new standard of care endocrine therapy 4. Adequate organ function as indicated by standard laboratory tests (CBC, liver function tests or CMP) allowing for systemic breast cancer treatment per treating oncologist 5. Patients with evaluable bone-only disease that is lytic or mixed lytic-sclerotic are eligible 6. Willing to comply with all study procedures and be available for the duration of the study 7. Disease may be measurable by RECIST 1.1 criteria or non-measurable. Lesion size must be at least 1cm. If only bone lesions present, they should be lytic or mixed lytic-sclerotic. If only liver lesions present, patient is not eligible. Exclusion Criteria: 1. Patients with active brain metastases 2. Patients with liver-only disease are not eligible due to high background liver activity related to the radiopharmaceutical's hepatobiliary route of elimination 3. Unable to lie flat during or tolerate PET/CT 4. Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP 5. Presence of liver failure as judged by patient's treating physician 6. Individuals who are pregnant, lactating, or planning on becoming pregnant during the study 7. Not suitable for study participation due to other reasons at the discretion of the investigators 8. Patients with progesterone-receptor negative disease defined as PR \<1 percent by IHC
Conditions Breast Cancer
Phase Not Applicable
Enrollment 172
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Drug: CDK4/6 inhibitor — CDK4/6 inhibitors

Primary Outcomes

  • Progression-Free Survival (PFS) (From the date of starting CDK4/6 inhibitor to the date of first documentation of progression or death (up to approximately 2.5 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-30
Completion: 2028-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 172 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RenJi Hospital
Contact Information
Study Contact:
Ziping Wu, MD
86(21)68385569
wuziping@renji.com
Qi Lu
86(21)68383364
rjllb3364@163.com
jinsong Lu, MD
lujingsong@renji.com
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Interventions
  • Drug: CDK4/6 inhibitor — CDK4/6 inhibitors
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality 200127 China
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 and older * Confirmed diagnosis of hormone receptor-positive breast cancer. * Subjects with locoregionally recurrent or metastatic disease not amenable to curative therapy. * Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease. * ECOG 0-2 * Adequate organ function Exclusion Criteria: * Subjects disable to swallow pills. * History of immunodeficiency disease
Conditions Locoregional Recurrence, Breast Cancer, ...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

In the Netherlands, breast cancer patients with locoregional recurrence (LRR) and intermediate- and high-risk factors are treated with surgery with or without postoperative re-irradiation with or without hyperthermia. Retrospective studies showed that 3-year locoregional control after postoperative re-irradiation with hyperthermia was 68-83%, and severe toxicity in up to 40% of LRR patients. Unfortunately, no prospective (randomized) data are available on clinical outcomes. Consequently, variation exists in hyperthermia-treatment and re-irradiation schedules. Prospective real-world data on oncological outcomes, toxicity and quality of life is highly needed for shared decision-making between patients and professionals. These data will be used in the design of a future randomized trial in high-risk LRR patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups. — Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.

Primary Outcomes

  • Patient-reported toxicity according to PRO-CTCAE in LRR patients (Five years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-01
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amsterdam UMC, location VUmc
Collaborators: Borstkanker Onderzoek Groep, Comprehensive Cancer Centre The Netherlands, Dutch Cancer Society
Principal Investigators:
  • Desiree Van Den Bongard, Dr (PRINCIPAL_INVESTIGATOR) - Amsterdam UMC
Contact Information
Study Contact:
Lisca Wurfbain, MD
+31 6-25414750
l.f.wurfbain@amsterdamumc.nl
Desiree Van Den Bongard, Dr
+31 6-25414750
h.j.vandenbongard@amsterdamumc.nl
Lisca Wurfbain, MD
l.f.wurfbain@amsterdamumc.nl
Amsterdam UMC
Interventions
  • Other: No interventions, patient-reported outcomes (PROMs) and toxicity will be collected in both groups. — Patients will receive standard of care. Patients need to fill in questionnaires, these are additional interventions for the included subject. Questionnaires for patient-reported outcomes (PROMs) and toxicity will be filled in one week before treatment, one week before re-irradiation, one week and three months after re-irradiation, one, two and five years after surgery.
Study Locations (1 sites)
Amsterdam UMC, Amsterdam, Netherlands
Eligibility Criteria
Inclusion criteria: * ≥ 18 years old * WHO performance scale ≤ 2 * Diagnosed with local +/- regional recurrence (LRR) (i.e. true recurrence or second primary) with high-risk tumor characteristics\* and previously treated with postoperative local +/- regional irradiation for primary breast cancer/previous recurrence with an indication for salvage mastectomy with/without postoperative re-irradiation (+/-hyperthermia)\*\* if re-irradiation: including overlap of re-irradiated volume with previous irradiated volume * Diagnosed with a chest wall recurrence and treated with local excision with/without NAST and postoperative re irradiation with/without hyperthermia. In patients with a clinical/radiological complete response after neoadjuvant systemic treatment, NO surgery and re irradiation (+/- hyperthermia) (since surgery is not possible in this group) * (Neo-)adjuvant systemic (NAST) treatment is allowed * Use of PET(FES/FDG)-CT for staging of nodal and disseminated disease * Oligometastases in lymph nodes in the mediastinum, neck, contralateral axillary/supraclavicular region (up to a maximal number of five) is allowed * Proficient in Dutch at a level allowing to understand the questionnaires and patient information sheet \* Definition of high-risk tumor characteristics are: * (Focal) irradical resection * All clinical and pathological stages except for low-risk LRR: - rcT1-2N0 - r(y)pT1-2N0 \*\* according to local clinical practice and/or shared decision making process Exclusion criteria: • Diagnosed with primary breast sarcoma
Conditions Triple Negative Breast Cancer
Phase Not Applicable
Enrollment 380
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The traditional neoadjuvant therapy for triple negative breast cancer is based on anthracycline, paclitaxel and carboplatin. Nowadays, immunotherapy combined with chemotherapy has become a new standard treatment, which not only benefits from pathological complete response (pCR), but also benefits from long-term survival. The standard chemotherapy combined with immunotherapy scheme recommended by the guidelines is TCb-AC combined with pabolizumab, but the complex chemotherapy scheme has the defects of long cycle and large adverse reactions, and the scheme of chemotherapy reduction has been explored. This project plans to adopt an ambispective cohort study, based on the large sample breast disease cohort database established by the breast center of Peking University People's Hospital, and retrospectively include the triple negative breast cancer patients with clinical stage T2 and above and/or lymph node positive who received neoadjuvant therapy (TCb-AC combined with immunotherapy, or TCb combined with immunotherapy) admitted to the center from January 1, 2019 to November 31, 2024. Patients of the same type from December 1, 2024 to December 31, 2028 were prospectively included. The efficacy and safety of different treatment regimens were compared.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • pathology complete response (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-01-01
Completion: 2028-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 380 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University People's Hospital
Principal Investigators:
  • shu wang (PRINCIPAL_INVESTIGATOR) - Peking University People's Hospital
Contact Information
Study Contact:
yuan peng, doctor
86+13671287670
13671287670@163.com
yuan peng, doctor
Peking University People's Hospital
shu wang
Peking University People's Hospital
Interventions
N/A
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality 100044 China
Eligibility Criteria
Inclusion Criteria: * 1\) Patients with triple negative breast cancer diagnosed by biopsy in Peking University People's Hospital; * 2\) The clinical stage was stage II or stage III (i.e. T2 and above, and/or lymph node positive, without distant organ metastasis); * 3\) Received treatment in our hospital and had hospitalization records; * 4\) Has signed and agreed to participate in the PKUPH breast disease cohort study. Exclusion Criteria: * 1\) Lack of clinical and pathological data (such as imaging data and pathological data); * 2\) Patients with metastatic breast cancer or bilateral breast cancer; * 3\) At the same time, they received anti-tumor therapy in other clinical trials, including endocrine therapy and targeted therapy; * 4\) Receiving other regimens besides the established neoadjuvant regimens
Conditions Esophageal Squamous Cell Carcinoma, High...
Phase PHASE1
Enrollment 150
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: IDE034 — IDE034

Primary Outcomes

  • Safety and tolerability of IDE034 in Part 1 dose escalation (21 days following the first dose of IDE034)
  • Safety and tolerability of IDE034 in Part 2 dose expansion (Approximately 20 months total study duration)
  • To evaluate preliminary anti-tumor activity of IDE034 in Part 2 dose expansion (Time Frame: Approximately 20 months total study duration)
  • To evaluate preliminary anti-tumor activity of IDE034 in Part 2 dose expansion (Time Frame: Approximately 20 months total study duration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-02-24
Completion: 2027-07-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IDEAYA Biosciences
Contact Information
Study Contact:
IDEAYA Clinical Trials
1-855-433-2246
IDEAYAClinicalTrials@ideayabio.com
Gerald Falchook
(615) 329-7274
SCRI.Webmaster@scri.com
Sarah Cannon Research Institute at HealthONE
Manish Patel
(941) 377-9993
scheduling@partnersimage.com
Florida Cancer Specialists
Interventions
  • Drug: IDE034 — IDE034
Study Locations (15 sites)
Sarah Cannon Research Institute at HealthONE, Denver, Colorado 80218 United States
Florida Cancer Specialists, Sarasota, Florida 34232 United States
Karmanos Cancer Institute, Detroit, Michigan 48201 United States
START New York Long Island, LLC, Lake Success, New York 11042 United States
SCRI Oncology Partners, Nashville, Tennessee 37203 United States
NEXT Texas LLC - Austin, Austin, Texas 78758 United States
START Dallas Fort Worth, LLC, Fort Worth, Texas 76104 United States
MD Anderson, Houston, Texas 77030 United States
NEXT Texas LLC - Houston, Houston, Texas 77054 United States
NEXT Texas LLC - Dallas, Irving, Texas 75039 United States
Eligibility Criteria
Inclusion Criteria: 1. Participant must be at least 18 years of age or the age of maturity per local regulations 2. Participants with advanced recurrent or metastatic solid tumors expressing B7-H3 and PTK7 in the following indications: NSCLC, ESCC, endometrial cancer, HGSOC, HNSCC, TNBC (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 \[HER2\] negative), CRC, and CRPC who have radiologically progressed or recurred on at least one line of therapy or is intolerant to additional effective standard therapies. 3. Archival tissue sample for testing 4. Measurable disease 5. Have Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. 6. Have adequate bone marrow and organ function. 7. Able to comply with contraceptive/barrier requirements Exclusion Criteria: 1. Known symptomatic brain metastases or leptomeningeal metastasis 2. Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose. 3. Have uncontrolled tumor-associated pain 4. Have clinically significant cardiac abnormalities and/or cerebrovascular disease (stroke) within 6 months before the first dose 5. Active uncontrolled infection 6. Have history of interstitial pneumonitis, current noninfectious pneumonitis requiring steroid therapy; known or suspected interstitial pneumonitis as seen on screening imaging; other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose. 7. Have history of severe infections within 4 weeks prior to the start of study treatment, including but not limited to bacteremia, severe pneumonia, or other serious infectious complications requiring hospitalization. 8. Have history of immunodeficiency, with a positive human immunodeficiency virus (HIV) test at screening. 9. Participants with known or suspected viral hepatitis 10. Have history of active tuberculosis within 1 year before enrollment 11. If participants had adverse reactions to previous antitumor treatment that have not recovered to guidelines of CTCAE Grade ≤ 1 and Grade 2 peripheral neurological symptoms 12. Have received chemotherapy within 3 weeks of first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 3 weeks before the first dose of IMP or other investigational products within 4 weeks of first dose of IMP 13. Administration of any of the following 1. Current use or anticipated need for food or drugs that are known strong CYP3A4/5 inhibitors or inducers 2. Have prior treatment with B7-H3 or PTK7 antibody-drug conjugate (ADC). 3. Have prior treatment with a topoisomerase I inhibitor (TOP1i), including an ADC with a TOP1i payload, within 6 months of first dose of IMP 4. Have received radiotherapy within 2 weeks prior to study entry 5. Have undergone major surgery or trauma within 4 weeks prior to study entry. 6. Have received live attenuated vaccine within 28 days prior to the first dose or are expected to receive live attenuated vaccine during the study treatment. 7. Female participants who are pregnant, lactating, or planning to become pregnant during the study period to 7 months after the last dose of IMP. 8. Are known to be allergic to any component or excipient of the IMP product or have a history of severe allergic reactions to other monoclonal antibody/fusion protein drugs. 9. Participants with complications in the eye including ulcers in the eye, and severe dry eye
Conditions Breast Neoplasms, HER2-positive Breast C...
Phase PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Phase II unicentric randomized trial which will include early HER2 positive breast cancer patients, candidate to neoadjuvant therapy with trastuzumab and pertuzumab. Circulating tumor cells will be collected at neoadjuvant therapy baseline. Patients with pathological complete response will be randomized in 1:1 ratio for adjuvant trastuzumab (arm A) versus trastuzumab + pertuzumab (arm B) in a two factorial design: group A, with HER2 positive CTCs and group B, with HER2 negative/absent CTCs.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Pertuzumab — Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)
  • Drug: Trastuzumab — Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts
  • Other: Circulating tumor cells — Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.

Primary Outcomes

  • HER2 therapy disease-free survival (From adjuvant therapy initiation to recurrence or death by any cause, whichever came first, assessed up to 5 years)
  • CTCs disease-free survival (From adjuvant therapy initiation to recurrence or death by any cause, whichever came first, assessed up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-03-01
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AC Camargo Cancer Center
Principal Investigators:
  • Marcelle G Cesca, MD (PRINCIPAL_INVESTIGATOR) - A.C. Camargo Cancer Center
Contact Information
Study Contact:
Marcelle G Cesca, MD
+551121895000
marcelle.cesca@accamargo.org.br
Ludmilla TD Chinen, PhD
+551121895000
ludmilla.chinen@accamargo.org.br
Marcelle G Cesca, MD
+551121895000
marcelle.cesca@accamargo.org.br
A.C. Camargo Cancer Center
Interventions
  • Drug: Pertuzumab — Adjuvant trastuzumab + pertuzumab (arm B of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline)
  • Drug: Trastuzumab — Adjuvant trastuzumab (arm A of the 2 cohorts: 1: HER2 positive CTCs at baseline and 2: HER2 negative/absent CTCs at baseline) Association with pertuzumab in arm B of the 2 cohorts
  • Other: Circulating tumor cells — Blood sample collection for examination of CTCs at baseline of neoadjuvant therapy. Tests for HER2 positivity will be done.
Study Locations (1 sites)
A.C. Camargo Cancer Center, São Paulo, 01525-001 Brazil
Eligibility Criteria
Inclusion Criteria: * HER2 positive breast cancer (hormone receptors positive or negative) * Stage I to III * Indication for neoadjuvant therapy with chemo (any regimen) + trastuzumab + pertuzumab * Breast surgery after neoadjuvant therapy * Preserved coagnition * ECOG 0-3 * For the randomization phase: pathological complete response (ypT0/ypTis and ypN0) * Agreement on participation and signature of de ICF Exclusion Criteria: * Contradindication for trastuzumab or pertuzumab * Adjuvant chemotherapy. Hormone therapy is allowed * Second primary tumor \< 5 years, with an exception for treated non-melanoma skin cancer, and in situ cervical cancer
Conditions Colorectal Cancer, Epithelial Ovarian Ca...
Phase PHASE1, PHASE2
Enrollment 71
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: [18F]FPyQCP — positron emission tomography (PET)/computed tomography (CT) imaging

Primary Outcomes

  • Assess radiation dosimetry of [18F]FPyQCP (Cohort A) (Up to 360 minutes post injection)
  • Assess the diagnostic performance of [18F]FPyQCP in the peritoneum (Cohort B) (Until completion of follow-up procedures, up to 42 days post injection)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-02-19
Completion: 2028-01-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 71 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Blue Earth Diagnostics
Collaborators: Medpace, Inc.
Principal Investigators:
  • Steven Rowe, MD (PRINCIPAL_INVESTIGATOR) - University of Texas Southwestern Medical Center
Contact Information
Study Contact:
Jamie MacKay, MD, PhD
+447350456887
jamie.mackay@blueearthdx.com
Evgenia Perkins
+19139576499
evgenia.perkins@blueearthdx.com
Steven Rowe, MD
University of Texas Southwestern Medical Center
Interventions
  • Drug: [18F]FPyQCP — positron emission tomography (PET)/computed tomography (CT) imaging
Study Locations (1 sites)
University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria: 1. Participants provide informed consent and confirm that they are able and willing to comply with all protocol requirements. 2. Participants must be ≥ 18 years and \< 80 years of age and competent to give informed consent. 3. Eastern Cooperative Oncology Group performance status ≤ 2. 4. Diagnosis of either CRC (confirmed by histopathology), GC (confirmed by histopathology), PDAC (confirmed by cytology or histopathology), ILC (confirmed by histopathology), or EOC (suspected or confirmed by cytology or histopathology). 5. Women of childbearing potential (WOCBP) should have a negative serum test at screening (Visit 1) and a negative urine pregnancy test at the PET/CT imaging visit (Visit 2) prior to \[18F\]FPyQCP administration. 6. WOCBP, and men who are sexually active with WOCBP, must agree to use a highly effective method(s) of contraception for the duration of the study 7. Cohort A specific: Participants with stage I-III (see Appendix 3) CRC, GC, PDAC, ILC, or EOC (stage IV disease is allowed in the setting of oligometastatic disease \[5 or fewer known metastases) as assessed by conventional imaging within 8 weeks of \[18F\]FPyQCP administration. 8. Cohort B specific: Conventional imaging performed within 8 weeks of screening and no later than 24 hours before \[18F\]FPyQCP administration and available for upload to the central imaging vendor, including, at a minimum, a contrast-enhanced CT that includes the abdomen and pelvis. 9. Either: 1. Treatment-naïve with at least stage IIB disease. Available biopsy sample or scheduled biopsy or surgical resection no later than Day 42. 2. Following neoadjuvant therapy (with at least stage IIB disease at initial presentation) with scheduled biopsy or surgical resection no later than Day 42. \[18F\]FPyQCP PET/CT imaging should be performed as close to scheduled procedure as clinically feasible. 3. Suspected recurrence after definitive therapy Exclusion Criteria: 1. Participants administered any radioisotope within 5 physical half-lives prior to \[18F\]FPyQCP administration. 2. Participants administered any other IMP within 2 weeks or 5 half-lives, whichever is longest, prior to \[18F\]FPyQCP administration. 3. Participants who have recently received any other contrast agent (\< 24 hours for intravenous agents and \< 5 days for oral agents) before the day of \[18F\]FPyQCP administration. 4. Participants with a history of severe claustrophobia or panic attacks when in confined spaces. 5. Known hypersensitivity to \[18F\]FPyQCP or any of its constituents. 6. Participants with any medical condition or other circumstances at screening or in their past medical history that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or study completion. 7. Known diagnosis of an autoimmune or inflammatory disorder that is expected to confound image interpretation per investigator judgment, excluding disorders directly related to the index cancer (e.g. tumor-associated pancreatitis or biliary stasis for PDAC). 8. Medical history of abdomino-pelvic or breast irradiation in the last 3 months. 9. Presence of any current implanted foreign material (e.g. stents, surgical clips) that may confound image interpretation per investigator judgment. 10. Significant renal or hepatic impairment. 11. Female participants who are breastfeeding, unless the participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the \[18F\]FPyQCP administration. 12. Cohort A Specific Exclusion Criteria: 12. No prior history of any other cancer, unless treated with curative-intent and disease-free for at least 5 years before Visit 1 (at least 1 year before Visit 1 for basal cell carcinoma, localized squamous cell carcinoma of the skin and in situ carcinoma of cervix).
Conditions Breast Cancer
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Acute post-mastectomy pain can cause adverse impacts on the patients as delayed discharge from post-operative recovery area, impairs pulmonary and immune functions, increases risk of ileus, thromboembolism, myocardial infarction and may lead to increased length of hospital stay. It is also an important factor leading to the development of chronic post mastectomy pain syndrome (PMPS) in almost half of the patients. Various regional anesthetic techniques have been described for postoperative pain relief after mastectomy, for example, thoracic epidural anesthesia, intercostal nerve block, paravertebral block, serratus anterior plane block, and pectoral nerve I and II blocks. All of them offer satisfactory pain relief after mastectomy. Erector spinae plane block is a novel para-spinal regional anesthesia technique, , promises to provide effective visceral as well as somatic analgesia after carcinoma of the breast surgeries. The ultrasound-guided rhomboid intercostal block sub-serratus plane block (RISS) is a novel analgesic technique The RISS block anesthetizes the lateral cutaneous branches of the thoracic intercostal nerves and can be used in multiple clinical settings for chest wall and upper abdominal analgesia

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Procedure: Ultrasound Guided Combined Rhomboid Intercostal Sub-serratus Plane Blocks — Ultrasound Guided Combined Rhomboid Intercostal Sub-serratus Plane Blocks
  • Procedure: Erector Spinae Plane Block — Erector Spinae Plane Block

Primary Outcomes

  • Total post-operative morphine consumption. (24 hours after the surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2026-04-01
Eligibility
Age: 18 Years – 60 Years
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute, Egypt
Principal Investigators:
  • Ayman Sharawy Abdelrahman Aboul Nasr, MD (PRINCIPAL_INVESTIGATOR) - National Cancer Institute Cairo University
Contact Information
Study Contact:
Ayman Sharawy Abdelrahman Aboul Nasr, MD
01282649008
ayman.sharawy@nci.cu.edu.eg
Asmaa Elsayed Khalil Elmoghazy, MD
01009468049
asmaakhalilmd2017@gmail.com
Ayman Sharawy AbdelRahman Aboul Nasr, MSc
+201282649008
dr.ayman_sh3rawy@yahoo.com
National Cancer Institute - Cairo University
Interventions
  • Procedure: Ultrasound Guided Combined Rhomboid Intercostal Sub-serratus Plane Blocks — Ultrasound Guided Combined Rhomboid Intercostal Sub-serratus Plane Blocks
  • Procedure: Erector Spinae Plane Block — Erector Spinae Plane Block
Study Locations (1 sites)
National Cancer Institute - Cairo University, Cairo, 11796 Egypt
Eligibility Criteria
Inclusion Criteria: 1. Breast cancer female patients. 2. ASA class II and III. 3. Age ≥ 18 and ≤ 60 Years. 4. Body mass index (BMI): \> 20 kg/m2 and \< 35 kg/m2. 5. Type of surgery; elective breast cancer surgery (either modified radical mastectomy or conservative breast surgery) combined with axillary dissection. Exclusion Criteria: 1. Patient refusal. 2. Age \<18 years or \>65 years. 3. BMI \<20 kg/m2 and \>35 kg/m2. 4. Major medical conditions. 5. Pregnancy or lactation.
Conditions Lung Cancer, Liver Cancer, Colorectal Ca...
Phase PHASE1, PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ipilimumab +pembrolizumab +durvalumab — This study has 3 subgroups: 1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks. 2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks. 3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks.

Primary Outcomes

  • Safety of 3 drugs combination treatment (5 years)
  • Progression-free survival (5 years)
  • Disease control rate (5 years)
  • Duration of remission (DOR) (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-11-01
Completion: 2035-10-30
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Principal Investigators:
  • Zhenfeng Zhang, MD, PHD (PRINCIPAL_INVESTIGATOR) - Second Affiliated Hospital of Guangzhou Medical University
Contact Information
Study Contact:
Zhenfeng Zhang, MD, PHD
+862039195966
zhangzhf@gzhmu.edu.cn
Bingjia He, MD
+862039195965
464677938@qq.com
Zhenfeng Zhang, MD, PHD
The Second Affiliated Hospital of Guangzhou Medical University
Interventions
  • Drug: ipilimumab +pembrolizumab +durvalumab — This study has 3 subgroups: 1. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via vein, every 3 weeks. 2. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks. 3. Ipilimumab +pembrolizumab +durvalumab is administrated with a total dose of 50-150mg via intra-tumor fine needle injection in 5 min, every 3 weeks.
Study Locations (1 sites)
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260 China
Eligibility Criteria
Inclusion Criteria: 1. Cytohistological confirmation is required for diagnosis of cancer. 2. Signed informed consent before recruiting. 3. Age above 18 years with estimated survival over 3 months. 4. Child-Pugh class A or B/Child score \> 7; ECOG score \< 2 5. Tolerable coagulation function or reversible coagulation disorders 6. Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L; PLT ≥50×10E9/L;INR \< 2.3 or PT \< 6 seconds above control;Cr ≤ 145.5 umul/L;Albumin \> 28 g/L;Total bilirubin \< 51 μmol/L 7. At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1. 8. Birth control. 9. Willing and able to comply with scheduled visits, treatment plan and laboratory tests. Exclusion Criteria: 1. Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks; 2. Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding; 3. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders; 4. Patients accompanied with other tumors or past medical history of malignancy; 5. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment; 6. Patients have poor compliance. Any contraindications for hepatic arterial infusion procedure: A.Impaired clotting test (platelet count \< 60000/mm3, prothrombin activity \< 50%). B.Renal failure / insufficiency requiring hemo-or peritoneal dialysis. C.Known severe atheromatosis. D.Known uncontrolled blood hypertension (\> 160/100 mm/Hg). 7. Allergic to contrast agent; 8. Any agents which could affect the absorption or pharmacokinetics of the study drugs 9. Other conditions that investigator decides not suitable for the trial.
Conditions Breast Cancer, PALB2-Mutated Breast Carc...
Phase PHASE1
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a type of antibody) * Olaparib (a type of PARP inhibitor)

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Axatilimab — Humanized immunoglobulin G (IgG)4 monoclonal antibody, 1.3 mL sterile, preservative free glass vials, via intravenous (into the vein) infusion per protocol.
  • Drug: Olaparib — Inhibitor of poly ADP ribose polymerase (PARP)1-3, 100 or 150 mg tablet, taken orally per standard of care.

Primary Outcomes

  • Maximum Tolerated Dose (MTD) (Up to 4 weeks)
  • Recommended Phase 2 Dose (RP2D) (Up to 4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-08-13
Completion: 2029-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: Incyte Corporation
Principal Investigators:
  • Filipa Lynce, MD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Filipa Lynce, MD
617-632-2335
filipa_lynce@dfci.harvard.edu
Filipa Lynce, MD
617-632-2335
Filipa_Lynce@DFCI.HARVARD.EDU
Dana-Farber Cancer Institute
Filipa Lynce, MD
Dana-Farber Cancer Institute
Interventions
  • Drug: Axatilimab — Humanized immunoglobulin G (IgG)4 monoclonal antibody, 1.3 mL sterile, preservative free glass vials, via intravenous (into the vein) infusion per protocol.
  • Drug: Olaparib — Inhibitor of poly ADP ribose polymerase (PARP)1-3, 100 or 150 mg tablet, taken orally per standard of care.
Study Locations (2 sites)
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Mayo Clinic, Rochester, Minnesota 55902 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically or cytologically confirmed metastatic or unresectable HER2 negative breast cancer, including HER2 low (IHC 2+/ISH-, IHC 1+). Any ER and PR expressions are permitted but must be known. Patients with hormone receptor (HR) positive disease, defined by either ER and/or PR positivity, must have progressed or are intolerant to all available endocrine therapy regimens, or not candidates to further endocrine therapy-based approaches. * Documented germline or somatic mutation in BRCA1, BRCA2, or germline mutation in PALB2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Testing may be completed by any CLIA-certified laboratory. * Participants must have evaluable or measurable disease per RECIST 1.1 criteria. NOTE: If the only site of measurable of disease has been previously irradiated, there must be evidence of post-radiation progression. * Patients must have received no more than 2 prior lines of cytotoxic chemotherapy for metastatic disease. Antibody drug conjugates will count towards prior lines of cytotoxic chemotherapy, as well as checkpoint inhibitors. For the purposes of this study, prior treatment with hormonal therapy and non-hormonal targeted therapy, as well as the combination of an aromatase inhibitor and everolimus, are not counted as a prior cytotoxic therapy. * Age ≥18 years. * ECOG performance ≤ 2. * Participants must meet the following organ and marrow function as defined below: * leukocytes ≥ 3000/mcL * absolute neutrophil count ≥ 1.5 x 109/L * platelets ≥ 100 x 109/L * total bilirubin ≤ 1.5x institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) ≤ 2.5x × institutional ULN or ≤5 × institutional ULN for participants with documented liver metastases * Creatinine clearance ≥ 51 mL/min (using Cockcroft-Gault equation) * Participants who are HBsAg positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks and have undetectable HBV viral load prior to registration. * Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention. * Hepatitis B screening tests are not required unless: * Known history of HBV infection * As mandated by local health authority * Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening. * Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to registration. * Hepatitis C screening tests are not required unless: * Known history of HCV infection * As mandated by local health authority * HIV-infected participants must have well-controlled HIV on ART, defined as: * a. Participants on ART must have a CD4+ T-cell count ≥350 cells/mm3 at the time of screening. * b. Participants on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening. * c. It is advised that participants must not have had any AIDS-defining opportunistic infections within the past 12 months. * d. Participants on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before study entry (Day 1) and agree to continue ART throughout the study. * e. The combination ART regimen must not contain any antiretroviral medications that interact with CYP3A4 inhibitors/inducers/substrates (https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers) * Ability to swallow and retain oral study medication * Patients with a history of treated central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria: * Disease outside the CNS is present * No clinical evidence of progression in the CNS since completion of CNS-directed therapy * Minimum of 2 weeks between completion of radiotherapy and Cycle 1 Day 1 * Recovery from significant (≥ Grade 3) acute toxicity with no requirement for escalating doses of corticosteroid over the 7 days prior to treatment start. * Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. * Female participants must be postmenopausal or must have a negative serum pregnancy test performed during screening. Postmenopausal is defined as: * Amenorrhoeic for 1 year or more following cessation of exogenous hormonal treatments * Luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels in the postmenopausal range for women under 50. * Radiation-induced oophorectomy with last menses \>1 year ago * Chemotherapy-induced menopause with \>1 year interval since last menses * Bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago * The effects of axatilimab and olaparib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men who are sexually active with WOCBP must agree to use adequate contraception for the duration of study participation and for 4 months after discontinuation of treatment. * Participants must be willing to undergo 3 research biopsies: at baseline, after 2 weeks of olaparib monotherapy, and after 2 cycles of combination therapy. If biopsy is not feasible or safe, OR if the only area accessible to biopsy is also the only site of measurable disease per RECIST 1.1 criteria, permission must be obtained from the DFCI sponsor- investigator to forgo the mandatory research biopsies. Formal eligibility exception would not be required in these circumstances. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Clinical progression on a PARP inhibitor, or within 12 months of receipt of a PARP inhibitor, including but not limited to olaparib. * Any previous treatment with CSF1R antibody. * Patients who have had prior systemic chemotherapy, immune therapy, or investigational therapy within three weeks of initiation of protocol therapy. Endocrine therapy must have been discontinued at least 7 days prior to initiation of protocol therapy. Patients may receive bisphosphonates or denosumab during the study. * Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1) with the exception of alopecia, are excluded. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to axatilimab or olaparib. * Participants receiving any medications or substances that are strong or moderate inhibitors or inducers of CYP450 enzyme(s) are ineligible. This also includes strong or moderate CYP3A inhibitors and inducers. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. * Participants with a QTcF of \>470msec on screening ECG * Patients with a history of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML * Participants unable to swallow orally administered medication and participants with gastrointestinal disorders that are likely to interfere with absorption of the study medications in the opinion of the treating investigator (e.g. malabsorption syndrome or major stomach or bowel resections). * Uncontrolled intercurrent illness including, but not limited to, uncontrolled hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/socia